PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35485167-3 2022 We previously reported that MEK1/2 inhibitor, U0126, has a protective effect on the development of atherosclerosis and vascular calcification. U 0126 46-51 mitogen-activated protein kinase kinase 1 Mus musculus 28-34 10711350-12 2000 The other MEK-1 inhibitor, U-0126, also inhibited both the thapsigargin- and TPA-induced histamine production in a concentration-dependent manner. U 0126 27-33 mitogen-activated protein kinase kinase 1 Mus musculus 10-15 10655493-5 2000 The increase in Sox9 levels induced by FGF2 was inhibited by a specific mitogen-activated protein kinase kinase (MAPKK)/mitogen-activated protein kinase/ERK kinase (MEK) inhibitor U0126 in primary chondrocytes. U 0126 180-185 mitogen-activated protein kinase kinase 1 Mus musculus 165-168 34099834-4 2021 Thromboembolic stroke was induced in C57 black/6J mice and the MEK1/2 inhibitor U0126 was administrated 3.5 h and rt-PA 4 h post stroke-onset. U 0126 80-85 mitogen-activated protein kinase kinase 1 Mus musculus 63-69 35504090-4 2022 Treatment with U0126, an inhibitor of MEK1/2 that phosphorylates and activates ERK1/2, during the differentiation, increased the mRNA levels of Myod and Myog with an increase in the protein level of myosin heavy chain (MYH)1/2. U 0126 15-20 mitogen-activated protein kinase kinase 1 Mus musculus 38-44 10766856-6 2000 Furthermore, we find that U0126, a specific inhibitor of the ERK-activating kinase, MEK-1/2, protects both HT22 cells and immature primary cortical neuron cultures from glutamate toxicity. U 0126 26-31 mitogen-activated protein kinase kinase 1 Mus musculus 84-91 10393094-5 1999 U0126, a novel and more potent inhibitor of MEK1/2, provoked a dose-dependent inhibition of ODC induction at lower concentrations with respect to PD98059. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 44-50 31784089-1 2020 Combined LXR ligand (T0901317) and MEK1/2 inhibitor (U0126) not only reduces atherosclerosis in apoE deficient mice, but also blocks LXR ligand-induced fatty liver and hypertriglyceridemia. U 0126 53-58 mitogen-activated protein kinase kinase 1 Mus musculus 35-41 31148200-5 2019 Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells. U 0126 184-189 mitogen-activated protein kinase kinase 1 Mus musculus 167-173 32009900-5 2019 We found that astrocytes and microglia strongly upregulate cell surface levels of ARTC2.1 and ADP-ribosylation of cell surface proteins in response to treatment with lipopolysaccharide (LPS) and the mitogen-activated protein kinase kinase (MEK) 1 and 2 inhibitor U0126, but do not respond to extracellular NAD+ with P2X7 activation and induction of cell death. U 0126 263-268 mitogen-activated protein kinase kinase 1 Mus musculus 199-252 32330731-8 2020 Gastrin activates ERK pathway in vivo and in vitro, and treatment with the MEK1 inhibitor U0126 blocked hypergastrinemia-mediated changes, including CCK2R-derived ECL cell hyperplasia in vivo as well as sphere formation and CgA expression in vitro. U 0126 90-95 mitogen-activated protein kinase kinase 1 Mus musculus 75-79 31682623-5 2019 MEK1/2 inhibitor (U0126) treatment suppressed the mRNA expressions of RA-induced Stra8 and meiotic marker genes (Rec8, Spo11, Dmc1, and Sycp3) in both XX and XY fetal germ cells. U 0126 18-23 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 31768875-10 2019 was completely prevented by the treatment with MEK1/2 inhibitors U0126 (5 mug/site, i.c.v. U 0126 65-70 mitogen-activated protein kinase kinase 1 Mus musculus 47-53 31336670-8 2019 Blocking A2A adenosine receptors by ZM241385 abolished the effect of BDNF, whereas additional stimulation of A2A receptors by CGS21680 increased MEPP amplitudes, which was prevented by MEK1/2 inhibitor U0126. U 0126 202-207 mitogen-activated protein kinase kinase 1 Mus musculus 185-191 30447218-9 2019 MEK1/2 inhibitor U0126 reduced the d-glucose-induced NFkappaB nuclear accumulation and TNFalpha expression in BV2 cells. U 0126 17-22 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 30946562-5 2019 Inhibition of Galphai/o signaling with pertussis toxin, as well as MEK1/2 inhibition with U0126, also reduced 5-HT1B-mediated ERK1/2 phosphorylation. U 0126 90-95 mitogen-activated protein kinase kinase 1 Mus musculus 67-73 30316871-5 2018 Using the rabbit polyclonal antibody against phospho-S299 of HSF4, we found that EGF and ectopic expression of MEK1 can increase the phosphorylation of HSF4/S299 and induce HSF4 sumoylation, and these effects are inhibited by U0126. U 0126 226-231 mitogen-activated protein kinase kinase 1 Mus musculus 111-115 29673908-8 2018 U0126, a MEK 1/2- signal cascade inhibitor, attenuated this phosphorylation and the positive inotropic effects of UTP in murine and human atrial preparations. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 9-16 29518531-9 2018 Pretreatment with the MEK1/2 inhibitor U0126 significantly suppressed the acute induction of Per2, Dec1, and Noct by EGF and also abolished the EGF-induced phase shift of the PER2::LUCIFERASE rhythm in NSCs. U 0126 39-44 mitogen-activated protein kinase kinase 1 Mus musculus 22-28 27045084-6 2016 In vitro, MEK1/2 inhibitors (PD98059 and U0126) substantially inhibited phosphorylation of MEK1/2 and ERK1/2. U 0126 41-46 mitogen-activated protein kinase kinase 1 Mus musculus 10-16 29436684-6 2018 The mitogen-activated protein kinase kinase 1/2 inhibitor U0126 inhibited Lf-induced ERK1/2 phosphorylation and repressed Lf-promoted myoblast proliferation. U 0126 58-63 mitogen-activated protein kinase kinase 1 Mus musculus 4-45 29397067-5 2018 Drp1 phosphorylation at serine 616 is increased in HD knock-in mouse derived striatal cells, which is abolished by treatment with U0126, a potent inhibitor of MEK1/2. U 0126 130-135 mitogen-activated protein kinase kinase 1 Mus musculus 159-165 29299041-9 2017 In addition, the inhibition of ERK1/2 phosphorylation by U0126, a highly selective inhibitor of both MEK1 and MEK2 and a type of MAPK/ERK kinase, up-regulated the expression of collagen VI, while it down-regulated the adipogenic-specific factors. U 0126 57-62 mitogen-activated protein kinase kinase 1 Mus musculus 101-105 29358904-8 2017 The BDNF induction by Kir4.1 siRNA transfection was suppressed by the MEK1/2 inhibitor U0126, but not by the p38 MAPK inhibitor SB202190 or the JNK inhibitor SP600125. U 0126 87-92 mitogen-activated protein kinase kinase 1 Mus musculus 70-76 28822602-12 2017 The MEK1/2 inhibitor U0126 prevented ARI from improving the behavioral impairment as well as enhancing NGF levels in OBX mice. U 0126 21-26 mitogen-activated protein kinase kinase 1 Mus musculus 4-10 28697633-7 2017 Treatment of cells with p38 inhibitor (SB203580), c-Jun N-terminal kinase inhibitor (SP600125), and MEK 1/2 inhibitor (U0126) did not significantly suppress the induction of HO-1 by ZnC. U 0126 119-124 mitogen-activated protein kinase kinase 1 Mus musculus 100-107 26916448-10 2017 SB203580 (p38 inhibitor) and U0126 (MEK1/2 inhibitor) significantly inhibited the PM2.5 -induced enhanced contraction and increased mRNA and protein expression of muscarinic receptors. U 0126 29-34 mitogen-activated protein kinase kinase 1 Mus musculus 36-42 27629357-6 2016 Pretreating the cells with the ERK kinase1/2 (MEK1/2) inhibitor U0126 obviously inhibited the proliferation of C2C12 cells. U 0126 64-69 mitogen-activated protein kinase kinase 1 Mus musculus 46-52 28034754-5 2017 Mechanistically, phosphorylation of MEK1/2 and ERK1/2 in NPCs was enhanced upon LXR agonist treatment, while abrogation of MEK/ERK phosphorylation by the inhibitors PD98059 and U0126 impaired the proliferation of wildtype NPCs in the presence or absence of LXR agonists. U 0126 177-182 mitogen-activated protein kinase kinase 1 Mus musculus 36-42 27045084-6 2016 In vitro, MEK1/2 inhibitors (PD98059 and U0126) substantially inhibited phosphorylation of MEK1/2 and ERK1/2. U 0126 41-46 mitogen-activated protein kinase kinase 1 Mus musculus 91-97 22875335-21 2013 Treatment with a MEK 1/2 inhibitor U0126 did not cause the inhibition of tumor growth as compared to untreated animals. U 0126 35-40 mitogen-activated protein kinase kinase 1 Mus musculus 17-24 26862884-7 2016 NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor. U 0126 69-74 mitogen-activated protein kinase kinase 1 Mus musculus 156-162 25562430-5 2015 Consistently, OSM-induced stabilization of the SOCS3 transcript is impaired in the presence of inhibitors that specifically block activation of MEK1/2 (U0126) and ERK1/2 (FR180204) or upon knock-down of ERK1/2 expression using specific siRNA. U 0126 152-157 mitogen-activated protein kinase kinase 1 Mus musculus 144-150 24947959-5 2015 In this study, we determined that U0126, a MEK1/2 inhibitor, increased tumor-free and survival rates and decreased growth of inoculated Lewis lung carcinomas in wild type mice. U 0126 34-39 mitogen-activated protein kinase kinase 1 Mus musculus 43-49 24947959-12 2015 Taken together, our study suggests that MEK1/2 inhibitors induce IFN-gamma production in an LXR-dependent manner and the induction of IFN-gamma expression can partially contribute to the anti-tumorigenic properties of U0126. U 0126 218-223 mitogen-activated protein kinase kinase 1 Mus musculus 40-46 22751110-9 2013 Inhibition of MEK 1/2 with UO126 completely restored ERbeta growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERbeta-induced proliferation. U 0126 27-32 mitogen-activated protein kinase kinase 1 Mus musculus 14-21 26356837-7 2015 Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction. U 0126 35-40 mitogen-activated protein kinase kinase 1 Mus musculus 14-20 26356837-7 2015 Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction. U 0126 35-40 mitogen-activated protein kinase kinase 1 Mus musculus 100-106 26356837-7 2015 Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction. U 0126 203-208 mitogen-activated protein kinase kinase 1 Mus musculus 14-20 26356837-7 2015 Inhibition of MEK1/2/ERK1/2 (1 muM U0126) and PI-3K/Akt (10 muM LY294002) signaling showed that the MEK1/2/ERK1/2 pathway via GSK-3beta exclusively was responsible for cardioprotection as an addition of U0126 prevented estrogen-induced GSK-3beta increased phosphorylation, resistance to mitochondrial Ca2+-overload, functional recovery and protection against infarction. U 0126 203-208 mitogen-activated protein kinase kinase 1 Mus musculus 100-106 23786209-7 2013 Moreover, the expression of both genes was downregulated by U0126, a MEK 1/2 inhibitor. U 0126 60-65 mitogen-activated protein kinase kinase 1 Mus musculus 69-76 22956516-7 2012 Pretreatment of granulosa cells with the MEK1/2 inhibitor U0126 demonstrated that cAMP-dependent increases in Areg, Ereg, Btc, and Il6 were mediated by extracellular regulated kinase 1/2 phosphorylation. U 0126 58-63 mitogen-activated protein kinase kinase 1 Mus musculus 41-47 23386286-10 2013 Furthermore, these effects were abolished by PI3K inhibitor LY294002 and MEK1/2 inhibitor U0126. U 0126 90-95 mitogen-activated protein kinase kinase 1 Mus musculus 73-79 22912494-7 2012 The production of inflammatory molecules induced by the knockdown of Omi was blocked by the MEK1-specific inhibitor U0126. U 0126 116-121 mitogen-activated protein kinase kinase 1 Mus musculus 92-96 22859407-7 2012 Furthermore, the effect of medetomidine (100 nM) was abolished by a preincubation with U-0126 (10 muM), a MEK1/2 inhibitor. U 0126 87-93 mitogen-activated protein kinase kinase 1 Mus musculus 106-112 22723831-8 2012 Inhibition of MEK1, using U0126, blunted this effect. U 0126 26-31 mitogen-activated protein kinase kinase 1 Mus musculus 14-18 22326785-10 2012 Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP. U 0126 10-15 mitogen-activated protein kinase kinase 1 Mus musculus 19-68 21945831-10 2012 The MEK1/2 inhibitors U0126 and PD98059 reversed the protective effects of COL1 and the decrease in proapoptotic proteins. U 0126 22-27 mitogen-activated protein kinase kinase 1 Mus musculus 4-10 22570747-8 2012 U0126 (an inhibitor of MEK-1/2) suppressed the LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA accumulation in BMMs. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 23-30 22427990-12 2012 Inhibition of Mek1/2 kinases with U0126, and the resulting inhibition of Erk1/2 phosphorylation, induced the increase of both the level of Bim-EL and apoptosis of cells seeded on the N-cadherin substrate, suggesting that Erk phosphorylation is necessary for cell survival. U 0126 34-39 mitogen-activated protein kinase kinase 1 Mus musculus 14-20 21711332-8 2011 Pretreatment of T lymphocytes with the MAPK p38 inhibitor SB203580 or the MEK1 inhibitor U0126 reduced the stimulatory effect of H2O2. U 0126 89-94 mitogen-activated protein kinase kinase 1 Mus musculus 74-78 20469933-5 2010 The MEK1/2 specific inhibitor U0126, but not NFkappaB inhibitors, reduced basal Tspo promoter activity in TSPO-rich steroidogenic cells (MA-10 Leydig), as well as basal and PMA-induced Tspo promoter levels in TSPO-poor nonsteroidogenic cells (NIH-3T3 fibroblasts). U 0126 30-35 mitogen-activated protein kinase kinase 1 Mus musculus 4-10 21558393-10 2011 Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. U 0126 35-40 mitogen-activated protein kinase kinase 1 Mus musculus 17-23 20589721-7 2010 MEK1/2 inhibitor (U0126) increased NOS2 expression, whereas GD1a treatment decreased it. U 0126 18-23 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 21439396-6 2011 Notably, Dox-induced up-regulation of IL-6 and GM-CSF was largely abolished after pretreatment of MTEC1 with either NF-kappaB inhibitor BAY11-7082 or MEK1/2 inhibitor U0126, supporting the involvement of the two pathways in the process. U 0126 167-172 mitogen-activated protein kinase kinase 1 Mus musculus 150-156 21053363-8 2010 We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway. U 0126 35-40 mitogen-activated protein kinase kinase 1 Mus musculus 18-24 20450880-6 2010 Since certain flavonoids are known to inhibit mitogen-activated protein kinases (MAPKs), we confirmed the contribution of MAPK/ERK kinase (MEK) to the AhR-mediated signal transduction by using U0126, an inhibitor of MEK1/2. U 0126 193-198 mitogen-activated protein kinase kinase 1 Mus musculus 216-222 20557427-6 2010 Stimulation of p90(RSK) in ischemic neurons was downstream of ERK activation because inhibition of MEK1 (MAP kinase/ERK kinase) with its inhibitor U0126 blocked phosphorylation of p90(RSK). U 0126 147-152 mitogen-activated protein kinase kinase 1 Mus musculus 99-103 20470842-5 2010 CPW-399 induction of delta subunit mRNA was reduced by prior treatment with either the MEK1/2 inhibitor U0126 or protein kinase A (PKA) inhibitors KT 5720 and H89. U 0126 104-109 mitogen-activated protein kinase kinase 1 Mus musculus 87-93 19913294-7 2010 Inhibition of ALP activity by HGF was rescued by U0126, a MEK1/2 inhibitor, indicating that HGF suppresses the BMP-2-Smad axis via activation of ERK1/2. U 0126 49-54 mitogen-activated protein kinase kinase 1 Mus musculus 58-64 19560459-6 2009 In addition, the expression of phosphorylated ERK1/2-pathway-proteins after incubation with GM-CSF and after inhibiting MEK1/2 with U0126 was analyzed. U 0126 132-137 mitogen-activated protein kinase kinase 1 Mus musculus 120-126 19733237-4 2009 Cells treated at early stage with the MEK-specific inhibitors, PD184352 and U0126, reduced both the MHC protein level and MCK promoter activity, demonstrating that high MEK1 activity at the mid-stage is required for myogenic differentiation. U 0126 76-81 mitogen-activated protein kinase kinase 1 Mus musculus 169-173 19560459-13 2009 Concerning signaling pathways, incubation with GM-CSF activates the ERK1/2 pathway, whereas inhibition of MEK1/2 with U0126 strongly decreased the phosphorylation downstream in the ERK1/2 pathway, and the antiapoptotic activity of GM-CSF in vitro. U 0126 118-123 mitogen-activated protein kinase kinase 1 Mus musculus 106-112 19712552-6 2009 The leptin-promoted GVBD and first polar body extrusion were blocked by a mitogen-activated protein kinase extracellular signal regulated kinase kinases (MEK)1/2 inhibitor, U0126, but not its inactive analogue U0124. U 0126 173-178 mitogen-activated protein kinase kinase 1 Mus musculus 107-161 19419315-7 2009 U0126 (MEK1/2 inhibitor) suppressed Pi-stimulated MGP and Fra-1 expression, indicating that ERK1/2 is required for Pi-dependent regulation of MGP and Fra-1. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 7-13 19428337-3 2009 In the present study we could elucidate the role of extracellular signal-related MAPK in the murine model of LPS-induced acute lung injury by using U0126, a specific inhibitor of MEK1/2, upstream kinases of ERK. U 0126 148-153 mitogen-activated protein kinase kinase 1 Mus musculus 179-185 19424626-9 2009 MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, blocked CTRP3/cartducin-induced cell proliferation. U 0126 40-45 mitogen-activated protein kinase kinase 1 Mus musculus 21-27 19162037-10 2009 Preinjection of PI3K inhibitor LY294002, MEK 1/2 inhibitor U0126 and JAK-2 inhibitor AG-490 partially abrogated the JWH-133 mediated infarct size reduction. U 0126 59-64 mitogen-activated protein kinase kinase 1 Mus musculus 41-48 18637712-8 2009 hsBAFF-stimulated B cell proliferation was obviously reduced by mitogen extracellular kinase 1/2 (MEK1/2, upstream of ERK1/2) inhibitor U0126. U 0126 136-141 mitogen-activated protein kinase kinase 1 Mus musculus 98-104 18419805-0 2008 The small molecule Mek1/2 inhibitor U0126 disrupts the chordamesoderm to notochord transition in zebrafish. U 0126 36-41 mitogen-activated protein kinase kinase 1 Mus musculus 19-23 18583944-6 2008 More importantly, when p-MEK1/2 activity was blocked by U0126, Plk1 lost its normal localization at the spindle poles, which might be one of the most vital factors causing the abnormal spindles in MEK1/2-inhibited oocytes. U 0126 56-61 mitogen-activated protein kinase kinase 1 Mus musculus 25-31 18583944-6 2008 More importantly, when p-MEK1/2 activity was blocked by U0126, Plk1 lost its normal localization at the spindle poles, which might be one of the most vital factors causing the abnormal spindles in MEK1/2-inhibited oocytes. U 0126 56-61 mitogen-activated protein kinase kinase 1 Mus musculus 197-203 18555587-5 2008 U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 7-13 18555587-5 2008 U0126 (MEK1/2 inhibitor) and PD98059 (MEK1 inhibitor) reduced the gAd-induced G-CSF mRNA expression and G-CSF protein production. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 7-11 18555587-7 2008 In addition, the gAd-induced phosphorylation of MEK1/2 and ERK1/2 was dramatically reduced by PD98059 and U0126, respectively. U 0126 106-111 mitogen-activated protein kinase kinase 1 Mus musculus 48-54 18419805-2 2008 RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo. U 0126 127-132 mitogen-activated protein kinase kinase 1 Mus musculus 46-50 18419805-2 2008 RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo. U 0126 127-132 mitogen-activated protein kinase kinase 1 Mus musculus 110-114 18419805-2 2008 RESULTS: Here, we reveal a potential role for Mek1/2 during notochord development by using the small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene Erk1/2 in vivo. U 0126 127-132 mitogen-activated protein kinase kinase 1 Mus musculus 110-114 18282182-11 2008 MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression. U 0126 136-141 mitogen-activated protein kinase kinase 1 Mus musculus 0-6 18367630-8 2008 Inhibition of the pathway mitogen-activated extracellular signal-regulated protein kinase (MEK) 1/2 with UO126 diminished the proliferation of the Sertoli and Leydig cells in vitro. U 0126 105-110 mitogen-activated protein kinase kinase 1 Mus musculus 26-99 18282182-11 2008 MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression. U 0126 136-141 mitogen-activated protein kinase kinase 1 Mus musculus 0-4 18282182-11 2008 MEK1/2 is immediately upstream of ERK1/2 and the MEK1 inhibitor PD98059 failed to attenuate COX-2 expression while the MEK1/2 inhibitor U0126 induced a slight decrease in COX-2 expression. U 0126 136-141 mitogen-activated protein kinase kinase 1 Mus musculus 119-125 17534697-6 2007 MAPK/ERK kinase 1/2 (MEK1/2) inhibitor, U0126, and p38 MAPK inhibitor, SB203580, blocked the CTRP3/cartducin-induced cell proliferation, and migration was blocked by U0126, but not the SB203580. U 0126 166-171 mitogen-activated protein kinase kinase 1 Mus musculus 21-27 17549607-9 2007 U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 9-15 16253760-4 2005 U0126, an inhibitor of MEK1/2, inhibited the TNF-alpha-induced activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and the metastatic properties in vitro without affecting cell proliferation. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 23-29 16909118-6 2007 In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126. U 0126 138-143 mitogen-activated protein kinase kinase 1 Mus musculus 43-49 16909118-6 2007 In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126. U 0126 138-143 mitogen-activated protein kinase kinase 1 Mus musculus 121-127 17694057-5 2007 Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis. U 0126 47-52 mitogen-activated protein kinase kinase 1 Mus musculus 70-123 17694057-5 2007 Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis. U 0126 47-52 mitogen-activated protein kinase kinase 1 Mus musculus 125-131 17636410-9 2007 Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP. U 0126 10-15 mitogen-activated protein kinase kinase 1 Mus musculus 19-25 17003343-7 2006 In addition, pharmacological inhibition of this pathway by coincubation of the palmitate-exposed cells with the MEK1/2 inhibitors PD98059 and U0126 prevented the downregulation of PGC-1alpha. U 0126 142-147 mitogen-activated protein kinase kinase 1 Mus musculus 112-118 16291739-4 2006 However, LIF and PGF2alpha can trigger increases in ERK1/2 activity, which are required for their mitogenic responses because U0126, a MEK1/2 inhibitor, prevents both ERK1/2 activation and induction of DNA synthesis by LIF or PGF2alpha treatment. U 0126 126-131 mitogen-activated protein kinase kinase 1 Mus musculus 135-141 16244358-8 2006 Activation of both ERKs and p38 MAPK by BPDE and attenuation of BPDE-induced p53 accumulation by U0126 or SB202190, specific inhibitor of MEK1/2 or p38 MAPK, indicate the role of ERKs and p38 MAPK in p53 accumulation. U 0126 97-102 mitogen-activated protein kinase kinase 1 Mus musculus 138-144 15908120-5 2005 U0126, an inhibitor of the MEK kinases, blocked the CART-stimulated activation of ERKs. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 27-30 15963474-7 2005 MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression. U 0126 17-22 mitogen-activated protein kinase kinase 1 Mus musculus 27-33 15896771-12 2005 U0126, an inhibitor of MEK1 protein, significantly reduced the phosphorylated forms of ERK1/2 and MB formation in vitro. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 23-27 15637050-7 2005 A subset of these SFK-dependent genes was induced by PDGF even in the presence of the MEK1/2 inhibitor U0126 or the PI3K inhibitor LY294002. U 0126 103-108 mitogen-activated protein kinase kinase 1 Mus musculus 86-92 15899786-7 2005 In addition, inhibition of ERK activation by exposing MEFs to the MEK1/2-specific inhibitors PD98059 and U0126 protected both KSR+/+ and KSR-/- MEFs cells from CDDP-induced apoptosis. U 0126 105-110 mitogen-activated protein kinase kinase 1 Mus musculus 66-72 15683736-5 2005 Furthermore, that the MAPK kinase (MEK) 1/2 inhibitor, U0126, blocked proliferation and induced death of B9 cells indicate that IL-6 may not exert its survival effect primarily through bcl-XL and emphasizes the key role of Ras-MAPK cascade elements in the regulation of myeloma growth/viability. U 0126 55-60 mitogen-activated protein kinase kinase 1 Mus musculus 22-43 15843032-6 2005 Treatment of myoblasts with LIF induced phosphorylation of ERK, and the LIF-induced inhibitory effect on myogenesis was blocked by pretreatment with U0126, a specific MEK inhibitor, and transient transfection with dominant negative (DN)-MEK1. U 0126 149-154 mitogen-activated protein kinase kinase 1 Mus musculus 237-241 15572029-6 2005 LIF could activate MEK1/2 and STAT3, but LIF-induced differentiation was blocked only by the MEK1/2-specific inhibitor U0126, indicating that the MEK/ERK pathway is necessary for LIF action in MPC cells. U 0126 119-124 mitogen-activated protein kinase kinase 1 Mus musculus 93-99 15380445-3 2004 Ox-LDL-induced proliferation of mouse peritoneal macrophages assessed by [3H]thymidine incorporation and cell counting assays was significantly inhibited by MEK1/2 inhibitors, PD98059 or U0126, and p38 MAPK inhibitors, SB203580 or SB202190, respectively. U 0126 187-192 mitogen-activated protein kinase kinase 1 Mus musculus 157-163 15367685-4 2004 Pretreating the cells with a MEK1-specific inhibitor (U0126) significantly attenuates this activity. U 0126 54-59 mitogen-activated protein kinase kinase 1 Mus musculus 29-33 14729583-8 2004 The p38 inhibitor SB203580 blocked TPA-mediated AP-1 activation, while the MEK1/2 inhibitor U0126 was not inhibitory despite suppression of c-Fos expression in mouse skin. U 0126 92-97 mitogen-activated protein kinase kinase 1 Mus musculus 75-81 15249198-3 2004 Insulin-induced accumulation of glycosaminoglycan and expression of chondrogenic differentiation markers, type II collagen, type X collagen, and aggrecan mRNA were inhibited by the MEK1/2 inhibitor (U0126) and the p38 MAP kinase inhibitor (SB203580). U 0126 199-204 mitogen-activated protein kinase kinase 1 Mus musculus 181-187 15059911-3 2004 Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2. U 0126 18-23 mitogen-activated protein kinase kinase 1 Mus musculus 27-70 14684387-5 2004 Interestingly, a persistent reduction in I kappa B alpha levels is also observed when the MEK1/2 inhibitor U0126 is coadministered with LPS, suggesting that components of the MEK/ERK pathway are involved in regulating I kappa B alpha protein expression and/or turnover. U 0126 107-112 mitogen-activated protein kinase kinase 1 Mus musculus 90-96 12786942-8 2003 Pretreatment of cells with a MEK1 inhibitor, U0126, also strongly inhibited IL-1beta-dependent secretion of MMP-9. U 0126 45-50 mitogen-activated protein kinase kinase 1 Mus musculus 29-33 14636892-3 2004 The induction of egr-1 correlated with a rapid ERK1/2 phosphorylation and was prevented with MEK1/2 inhibitors PD 98059 and UO126. U 0126 124-129 mitogen-activated protein kinase kinase 1 Mus musculus 93-99 14738765-5 2004 Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity. U 0126 61-66 mitogen-activated protein kinase kinase 1 Mus musculus 110-114 14654170-7 2003 However, after the inhibition of MAPK/extracellular signal-regulated kinase kinase 1/2 (MEK1/2) with U0126, apoptosis was observed when TNF-alpha was added. U 0126 101-106 mitogen-activated protein kinase kinase 1 Mus musculus 88-94 14673008-7 2003 Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1. U 0126 62-67 mitogen-activated protein kinase kinase 1 Mus musculus 44-51 14673008-7 2003 Intrahippocampal injection of the selective Mek-1/2 inhibitor U0126 or CRF2 antagonist antisauvagine-30 (aSvg-30) prevented stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1. U 0126 62-67 mitogen-activated protein kinase kinase 1 Mus musculus 162-169 14511112-5 2003 U0126, an antagonist for MEK1/2, a kinase that phosphorylates the extracellular signal-regulated kinases ERK1/2, decreased IFN gamma-induced NO production. U 0126 0-5 mitogen-activated protein kinase kinase 1 Mus musculus 25-31 12893744-10 2003 Accordingly, inhibitors of FGFR signaling, including the FGFR1 tyrosine kinase inhibitor SU 5402, the MEK1/2 inhibitor U0126, and the protein kinase C inhibitor GF109 all prevented cardiomyocyte differentiation in fgfr1+/- EBs without affecting the expression of the hematopoietic/endothelial marker flk-1. U 0126 119-124 mitogen-activated protein kinase kinase 1 Mus musculus 102-108 12844482-10 2003 The MEK1/2 inhibitor U0126 strongly inhibited NF-kappaB activation, while p38 inhibitor SB203580 failed to block TPA-induced NF-kappaB activation in mouse skin. U 0126 21-26 mitogen-activated protein kinase kinase 1 Mus musculus 4-10 12906713-15 2003 Activated MEK1-transfected cells were more resistant to UO126-induced apoptosis in vitro and formed larger tumors in SCID mice than mock-transfected cells. U 0126 56-61 mitogen-activated protein kinase kinase 1 Mus musculus 10-14 12787125-9 2003 Furthermore, a specific MEK1/2 inhibitor, U0126, mimicked the effect of CX-659S. U 0126 42-47 mitogen-activated protein kinase kinase 1 Mus musculus 24-30 12646577-12 2003 PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF2 alpha. U 0126 11-16 mitogen-activated protein kinase kinase 1 Mus musculus 32-35 12606479-8 2003 Furthermore, addition of U0126, an inhibitor of MEK 1/2, abolished the increase in VEGF production stimulated by both hCG and 8Br-cAMP. U 0126 25-30 mitogen-activated protein kinase kinase 1 Mus musculus 48-55 12521992-7 2003 Accordingly, the MEK1/2 inhibitor U0126 potently inhibited the collagen-induced aggregation of transgenic platelets when stirred or when perfused over a collagen surface. U 0126 34-39 mitogen-activated protein kinase kinase 1 Mus musculus 17-23 12370392-15 2002 Adhesion was partially inhibited by the mitogen-activated protein kinase kinase 1/2 inhibitor U0126 (24.5 +/- 3.3%; n = 3) and the p38 inhibitor SB203580 (25.1 +/- 10.4%; n = 3). U 0126 94-99 mitogen-activated protein kinase kinase 1 Mus musculus 40-81 12074563-3 2002 Inhibition of MEK1/2 with a specific inhibitor, U0126, parthenogenetically activated mouse eggs, producing phenotypes similar to Mos(-/-) parthenogenotes (premature, unequal cleavages and large polar bodies). U 0126 48-53 mitogen-activated protein kinase kinase 1 Mus musculus 14-20 11511524-8 2001 The pathway by which PDGF induced Egr-1 involved the mitogen-activated protein kinase kinase-1 (MEK1) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), because the effect of PDGF on the induction of Egr-1 was blocked by U0126, a specific MEK1 inhibitor. U 0126 231-236 mitogen-activated protein kinase kinase 1 Mus musculus 53-94